SmartCella Holding AB
Danijal Topcic is a seasoned professional in the field of biotechnology with extensive experience in stem cell research and process development. Currently serving as the MSAT/Process Development Manager at Procella Therapeutics AB since February 2019, Danijal oversees the transition of scientific knowledge from development to GMP-compliant manufacturing for regenerative therapies. Previously, Danijal held roles such as Senior Scientist and Scientist at Procella Therapeutics, contributing to the creation of process platforms for innovative stem cell therapies and collaborating with AstraZeneca on treatments for heart failure. Prior experience includes a Senior Researcher/Manager role at Karolinska Institutet, a Postdoctoral Research Fellow position at Ludwig Cancer Research, and research work at Baker Heart and Diabetes Institute and the University of Sydney. Danijal holds a PhD in Molecular Cell Biology from the University of Melbourne and a Bachelor of Science (Honours) in Molecular Biology/Biotechnology from Victoria University.
This person is not in any teams
SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.